These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23054975)

  • 1. Interactions of everolimus and sorafenib in pancreatic cancer cells.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Ma WW; Jusko WJ
    AAPS J; 2013 Jan; 15(1):78-84. PubMed ID: 23054975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Ma WW; Jusko WJ
    Pharm Res; 2013 Mar; 30(3):707-13. PubMed ID: 23151723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
    Tuncyurek P; Mayer JM; Klug F; Dillmann S; Henne-Bruns D; Keller F; Stracke S
    Eur Surg Res; 2007; 39(6):380-7. PubMed ID: 17700025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
    Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
    Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Thng CH; Chow P; Ong HS; Chung A; Soo KC
    J Cell Mol Med; 2009 Aug; 13(8B):2673-2683. PubMed ID: 19220580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
    Mao WF; Shao MH; Gao PT; Ma J; Li HJ; Li GL; Han BH; Yuan CG
    Acta Pharmacol Sin; 2012 Oct; 33(10):1311-8. PubMed ID: 22941289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.